ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Boehringer Ingelheim Enrolls First Patient to Evaluate nintedanib for Pediatric Fibrosing ILD
August 17, 2020Boehringer Ingelheim announced the first patient has enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents between 6 and 17 years old with clinically significant fibrosing ... -
Ofev® (nintedanib) approved by FDA to treat interstitial lung diseases
March 11, 2020The FDA has granted marketing authorisation for Ofev, as the first treatment for patients with chronic fibrosing interstitial lung diseases (ILDs).
Pharma Sources Insight January 2025
